Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Posted On: 2020-10-28 09:23:05


(CMP - Rs. 5062, MCap - Rs. 84167 crore)

Dr Reddy's Laboratories' Q2FY21 revenues were better than I-direct estimates on all fronts on the back of strong growth in US, Europe and Indian markets and better than expected operational performance.

Q2FY21 Earnings Summary

- Revenues grew 2.0% YoY to Rs. 4911 crore (I-direct estimate: Rs. 4564 crore) mainly due to strong growth in US, Europe and Indian markets partially offset by high base effect in Q2FY20 (divestiture of certain proprietary product brands). The PSAI segment also posted a robust 19.7% YoY growth to Rs. 851 crore (I-Direct estimate: Rs. 817 crore). US revenues grew 28.5% YoY to Rs. 1833 crore (I-Direct estimate: Rs. 1736 crore) on the back of rupee depreciation and new product launches. Domestic revenues grew 21.5% YoY to Rs. 912 crore (I-direct estimate: Rs. 801 crore) due to Wockhardt integration and Covid related products. Europe revenues grew 35.8% YoY to Rs. 375 crore (I-Direct estimate: Rs. 346 crore) due to new launches and currency tailwinds. Russia & Other CIS revenues grew 3.4% YoY to Rs. 600 crore (I-Direct estimate: Rs. 493 crore). ROW sales grew 6.5% YoY to Rs. 264 crore (I-Direct estimate: Rs. 297 crore)

- EBITDA margins expanded 144 bps YoY to 23.5% (I-Direct estimate: 22.7%) due to lower other expenses partially offset by higher raw material and staff costs. Subsequently, EBITDA grew 8.7% YoY to Rs. 1156 crore against I-direct estimate of Rs. 1037 crore

- Net profit de-grew 30.3% YoY to Rs. 772 crore (I-direct estimate: Rs. 608 crore). Delta vis--vis EBITDA was mainly due to negative tax in Q2FY20

The management remains committed to working on cost rationalisation, especially on the SGN&A front and calibrating of R&D spend more towards Global Generics front & Biosimilars and lower towards proprietary products. Key growth drivers in the near term would be key launches across geographies besides continuing growth momentum in Global Generics especially in India and Russia.

We would be coming out with a detailed report post interaction with the management.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4949.8 as compared to the previous close of Rs. 5100.3. The total number of shares traded during the day was 151548 in over 12790 trades.

The stock hit an intraday high of Rs. 5148 and intraday low of 4921.5. The net turnover during the day was Rs. 768034167.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com



Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking

Lakshmi Vilas Bank - Angel Broking

WIPRO Buyback record date announcement - Angel Broking

TCS buyback record date announcement - Angel Broking

Banks Sector Update - Collection efficiency - a positive surprise! - HDFC Securities

Quant Pick - Max Financial Services - ICICI Direct

Graphite India - Q2FY21 Result Update - ICICI Direct

Gladiator Stocks - Maruti Suzuki India - ICICI Direct

Exide Industries - Q2FY21 Result Update - ICICI Direct

Mishra Dhatu Nigam - Execution outlook remains strong - ICICI Securities



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019